Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- 87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 9·4 months (6·8-13·6) in selumetinib group and 5·2 months (95% CI 3·8-non-calculable) in placebo group (hazard ratio [HR] for death 0·80, 80% CI 0·56-1·14; one-sided p=0·21). Median PFS was 5·3 months (4·6-6·4) in selumetinib group and 2·1 months (95% CI 1·4-3·7) in placebo group (HR for progression 0·58, 80% CI 0·42-0·79; one-sided p=0·014). An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<0·0001).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/999
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Docetaxel,Selumetinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23200175
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Docetaxel | Sensitivity | true |
| Selumetinib | Sensitivity | true |